Exploring the n orepinephrine to a ngiotensin II c onversion r atio in p atients with v asodilatory...
Exploring the n orepinephrine to a ngiotensin II c onversion r atio in p atients with v asodilatory h ypotension: A p ost- h oc a nalysis of the ARAMIS t rial
About this item
Full title
Author / Creator
Publisher
Philadelphia: Elsevier Limited
Journal title
Language
English
Formats
Publication information
Publisher
Philadelphia: Elsevier Limited
Subjects
More information
Scope and Contents
Contents
PurposeAngiotensin II is approved for catecholamine-refractory vasodilatory shock but the conversion dose ratio from norepinephrine to angiotensin II remains unclear.MethodsWe conducted a post-hoc analysis of the Acute Renal effects of Angiotensin II Management in Shock (ARAMIS) trial involving patients with vasodilatory hypotension. We determined...
Alternative Titles
Full title
Exploring the n orepinephrine to a ngiotensin II c onversion r atio in p atients with v asodilatory h ypotension: A p ost- h oc a nalysis of the ARAMIS t rial
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2899652476
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2899652476
Other Identifiers
ISSN
0883-9441
E-ISSN
1557-8615
DOI
10.1016/j.jcrc.2023.154453
